• voluntarily participate in the study and sign informed consent;

• age over 18 years old (including the cut-off value), regardless of gender;

• advanced malignant solid tumor pathologically and/or histologically diagnosed with malignant pleural effusion requiring drainage confirmed by histopathology or cytopathology (metastatic or primary);

• the original pleural cavity malignant tumor after standard treatment failure, or top treatment;

• signed informed consent not line within a month before the chest cavity medicine injection, but does not exclude the diagnostic puncture;

• The subjects voluntarily provided sufficient tumor cells in the pathological section of the primary lesion and/or pleural effusion for B7-H3 expression detection, and the tumor cells in the pathological section of the primary lesion or malignant pleural effusion were positive for B7-H3 expression;

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-2;

• within 7 days before treatment laboratory meet the following criteria:

⁃ Routine blood (14 days) :

• Absolute neutrophil count (ANC) ≥1.5×109 /L;

• platelet count (PLT) or 80 x 109 / L;

• hemoglobin (HGB) or 80 g/L (allowing blood transfusion and use erythropoiesis agent). The presence of active bleeding or other ongoing conditions that result in increased red-cell destruction or impaired production may require repeated transfusions or red-cell therapy, and patients had to discuss their eligibility with the sponsor on an individual basis before enrollment.) ;

⁃ Liver:

• total bilirubin (TIBC) or less 2 times the upper limit of the normal range (ULN);

• no liver metastasis, AST and ALT 3 x ULN or less; ALT and AST≤5 times ULN in the presence of liver metastasis;

⁃ Kidney:

• Serum creatinine (Cr) ≤ 2 times ULN; Or creatinine clearance (CrCL) ≥ 50 mL/min (estimated by Cockcroft-Gault formula);

• Blood coagulation function:

• international standardization ratio (INR) or prothrombin time (PT) 1.3 x ULN or less;

• Partial activated thromboplastin time (APTT) ≤ 1.5 times ULN; 9) toxicity from previous systemic therapy returned to grade 1 or less or to baseline before the first dose (except alopecia); 10) Fertile men and women of childbearing age must agree to use reliable contraception from the time they provide informed consent until 180 days after the last dose of MT027 cell injection; Women of childbearing age included those who were premenopausal and those within 2 years of menopause.